Levosimendan in acute decompensation of anthracycline-induced cardiotoxicity

García, José Ángel Brandariz; Simvoulidis, Luiz Fernando Nogueira; Salluh, Jorge I.; Hansen, Maria H.A.; Feres, Guilherme Alvarenga; Holanda, Gustavo Sampaio de; Souza, Roberto C.S.; Toscano, Luisa; Soares, Márcio

doi:10.1016/j.ijcard.2006.07.051

Cited by 12 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Orally active iron chelators and flavonoids as well as erythropoietin have been proved to protect cardiac myocytes against anthracycline‐ induced apoptosis 32 . In acute decompensation of anthracycline cardiotoxicity, the novel cardioprotective agent levosimendan seems to be effective, but new studies are needed to confirm its efficacy 33 . Until then, we suggest that all patients receiving epirubicin chemotherapy, even at low doses, should be under the close care of a cardiologist and have their diastolic function monitored closely and periodically.…”

Section: Discussionmentioning

confidence: 99%

“…32 In acute decompensation of anthracycline cardiotoxicity, the novel cardioprotective agent levosimendan seems to be effective, but new studies are needed to confirm its efficacy. 33 Until then, we suggest that all patients receiving epirubicin chemotherapy, even at low doses, should be under the close care of a cardiologist and have their diastolic function monitored closely and periodically. Congestive Heart Failure® (ISSN 1527-5299) is published bimonthly (Feb., April, June, Aug., Oct., Dec.) by Le Jacq, a Blackwell Publishing imprint, located at Three Enterprise Drive, Suite 401, Shelton, CT 06484.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Altered Left Ventricular Diastolic Performance in Oncologic Patients Treated With Epirubicin

Rădulescu

Pripon

Parv

et al. 2007

Congestive Heart Failure

View full text Add to dashboard Cite

Anthracyclines confer an increased risk of cardiotoxicity. The authors evaluated left ventricular (LV) performance in patients treated with epirubicin. Sixty-eight patients with malignancies (study group), treated with epirubicin < or = 450 mg/m2, and a matched control group of 68 cancer patients who had not started chemotherapy were evaluated by Doppler echocardiography. The authors assessed LV diastolic function by measuring the transmitral flow: the maximal velocity of the E and A waves, the Emax/Amax ratio, the pressure half time of E wave (PHT), and the isovolumic relaxation time (IVRT). Global LV ejection fraction (LVEF) was estimated to determine the systolic performance. The authors documented alterations of the LV diastolic performance in the study group by finding a significant decrease in Emax, whereas Amax was significantly increased. Prolonged PHT and IVRT were also certified in the epirubicin-treated group compared with controls. No significant variation in LVEF between the 2 groups was detected.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Altered Left Ventricular Diastolic Performance in Oncologic Patients Treated With Epirubicin

Rădulescu

Pripon

Parv

et al. 2007

Congestive Heart Failure

View full text Add to dashboard Cite

show abstract

“…Levosimendan has now been accepted as a treatment option in acute decompansated heart failure. There are reports of successful levosimendan use in myocardiopathy due to acute Chagas’ disease, peripartum cardiomyopathy and anthracycline‐induced cardiotoxicity …”

Section: What Is New and Conclusionmentioning

confidence: 99%

Rapid recovery from acute myocarditis under levosimendan treatment: report of two cases

et al. 2013

View full text Add to dashboard Cite

show abstract

“…There are case reports of successful levosimendan use in cardiomyopathy due to acute Chagas' disease, peri-partum cardiomyopathy, anthracycline-induced cardiotoxicity and TC [6,[10][11][12][13][28][29][30]. In the present study, it was demonstrated that levosimendan can be used safely and efficiently in TC as a non-catecholaminergic inotrope agent for faster symptomatic and clinical improvement for the first time.…”

Section: Discussionmentioning

confidence: 49%